Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Editorial

A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Atsumasa Komori

Clin Mol Hepatol. 2025;31(2):584-588. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0945

View: 730 Download: 38 Crossref: 1

Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Nilanga Nishad

Clin Mol Hepatol. 2025;31(2):581-583. Published online November 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0942

View: 628 Download: 31 Crossref: 1

Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis”

Kyung-Ah Kim

Clin Mol Hepatol. 2025;31(1):275-276. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0827

View: 939 Download: 42

Original Article

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial

Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park

Clin Mol Hepatol. 2025;31(1):119-130. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0629

View: 1822 Download: 234 Web of Science: 1 Crossref: 1

1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

MOST VIEWED (Last 6 months)

Viewed By 8997	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7682	MAFLD: How is it different from NAFLD?
Viewed By 5548	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5155	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4614	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

+more

MOST CITED (2023-2025)

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 293	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 204	MAFLD: How is it different from NAFLD?
Cited By 103	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes

+more

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: cmh_journal@ijpnc.com

COUNTER

TODAY : 472

TOTAL : 2652793